Serum Sclerostin Level & Treatment of Vitamin D Deficiency
NCT ID: NCT01553344
Last Updated: 2014-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2012-03-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Healthy premenopausal Patients with Vitamin D deficiency diagnosed and routinely treated with calcium and vitamin D will be included in the study. This is an observational study. The serum sclerostin levels will be measured before and after Vitamin D treatment.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will be completed with patients with Vitamin D deficiency. An intravenous cannula will be inserted into the antecubital vein. Blood samples will be obtained before and after treatment.
Serum will be collected and will be centrifuged for 15 minutes at 1000Xg within 30 minutes of collection. Aliquots of serum will be added to eppendorf tubes and stored at -20°C.
Serum sclerostin levels will be measured using a Human Sclerostin ELISA kit (Cusabio, Catalog No: CSB-E13146h, Newark, DE, USA). All assays will be performed according to the manufacturer's instructions. The minimum detectable concentration of human sclerostin is typically \<0.012 ng/ml. Intra-assay precision is less than 8%.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum 25(OH)D \< 10 ng/mL
Exclusion Criteria
* Tumor-induced osteomalacia (hypophosphatemia)
* Hypothyroidism
* Hepatic / renal disease
* Primary hyperparathyroidism
* Fibromyalgia
* Polymyalgia rheumatica
* Serum 25(OH)D \> 10 ng/mL
* Vitamin D and calcium treatment commenced prior to study participation
20 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bagcilar Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ilhan Karacan, Clinical Associated Professor
Chief of Physical Med & Rehab Clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MUHARREM CIDEM, MD
Role: PRINCIPAL_INVESTIGATOR
Bagcilar Training & Research Hospital Istanbul, Turkey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bagcilar Training & Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BEAH FTR -7
Identifier Type: -
Identifier Source: org_study_id